Skip to Main Content

A former Sun Pharmaceutical sales employee has a filed a lawsuit claiming retaliation for objecting to alleged off-label marketing practices, the second time in four months that one of the world’s largest generic drug makers has been accused of such a move amid rising scrutiny of its business practices.

In her lawsuit, Sandra Hagenbrock, a former national account director, claimed that company managers flouted internal policies prohibiting off-label marketing. Instead, the drug maker tried to “aggressively solicit opportunities to present off-label information to decision-makers (notably, physicians and health plans) about its drugs.” Among them was the Yonsa treatment for prostate cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!